2세에서 12세 미만의 바이러스 억제 HIV-1 감염 아동을 대상으로 한 경구 및 지속성 주사용 카보테그라비르 및 릴피비린 연구
2세에서 12세 미만의 바이러스 억제 HIV-1 감염 아동을 대상으로 경구 및 지속형 주사용 카보테그라비르와 릴피비린의 안전성, 내약성, 수용성 및 약동학에 대한 I/II상 연구
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a Phase I/II, multicenter, open-label, non-comparative study to evaluate the safety, tolerability, acceptability, and PK of oral CAB and oral RPV followed by long-acting injectable CAB (CAB LA) and long-acting injectable RPV (RPV LA) to propose the weight-band dosing in virologically suppressed children living with HIV-1 aged two to less than 12 years. The study will also assess the long-acting injectable regimen with and without an oral lead-in period in the same study population.
Following completion of the study, if it is not possible for participants to access injections of CAB LA and RPV LA from non-study sources all participants may enter a Study Safety Extension (SSE) period. During the SSE period ongoing safety information to monitor for toxicities will be collected.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Johannesburg, 남아프리카, 1862
- CRS 8052, Soweto IMPAACT CRS
-
Johannesburg, 남아프리카, 2001
- Site 8051, Wits RHI Shandukani Research Centre CRS
-
-
KwaZulu-Natal
-
Umlazi, KwaZulu-Natal, 남아프리카, 4066
- Site 30300, Umlazi CRS
-
-
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Site 5030, Emory University School of Medicine NICHD CRS
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38105
- Site 6501, St. Jude Children's Research Hospital CRS
-
-
-
-
-
Gaborone, 보츠와나
- Site 12701, Gaborone CRS
-
Molepolole, 보츠와나
- Site 12702, Molepolole CRS
-
-
-
-
-
Belo Horizonte, 브라질, 30.130-100
- Site 5073, School of Medicine, Federal University of Minas Gerais
-
Rio de Janeiro, 브라질, 21941-912
- CRS 5071, Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS
-
-
-
-
-
Chiang Mai, 태국, 50200
- CRS 31784, Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
-
Chiang Rai, 태국, 57000
- Site 5116, Chiangrai Prachanukroh Hospital NICHD CRS
-
-
Bangkoknoi
-
Bangkok, Bangkoknoi, 태국, 10700
- Siriraj Hospital, Mahidol University NICHD CRS (Site #5115)
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria, Step 1: Entry for Cohort 1, Cohort 2a, and Cohort 2b
- Parent or legal guardian is willing and able to provide written permission for child's study participation and, when applicable per institutional review board/ethics committee (IRB/EC) policies and procedures, child is willing and able to provide written assent for study participation.
Note: All sites must follow all applicable IRB/EC policies and procedures; for US sites, this includes single IRB (sIRB) policies and procedures.
- Age two years old to less than 12 years old at entry
- Body weight ≥10 kg and <40 kg at entry
- At entry, willing and able to comply with the study visit schedule and other study requirements, as determined by the site investigator or designee.
- Confirmed HIV-1-infection based on documented testing of two samples collected from two separate blood collection tubes per Sample #1 and Sample #2 requirements. Test results may be obtained from medical records or from testing performed during the study screening period
- Has been on a stable unchanged ART regimen consisting of two or more drugs from two or more antiretroviral drug classes for at least six consecutive months (defined as 180 consecutive days) prior to entry.
- Has no prior history of switching ART regimens for reasons related to treatment failure based on parent/guardian report and/or available medical records.
Note: Participants undergoing dose modifications for growth or who have switched to a new formulation due to toxicity, tolerability, or changes in national treatment guidelines are considered eligible per this inclusion criterion. Treatment failure should be defined by local guidelines.
-
From a specimen collected less than six months (defined as within 179 days) prior to entry, has at least one of the following documented plasma HIV-1 RNA results:
- <50 copies/mL, or
- less than the lower limit of detection of the assay
-
From a specimen collected in the 6-18 months (defined as 180 to 545 days) prior to entry, has at least one of the following documented plasma HIV-1 RNA results:
- <50 copies/mL, or
- less than the lower limit of detection of the assay
-
At screening, a documented plasma HIV-1 RNA <50 copies/mL.
Note: HIV-1 RNA test results at screening cannot be used to satisfy previously listed inclusion criterion. If participant does not have a documented HIV-1 RNA test result at screening that satisfies previously listed criteria, they should be referred for standard of care testing and return at a later date for screening.
-
Has normal, Grade 1, or Grade 2 results for all the following laboratory tests at screening (i.e., within 28 days prior to entry) based on grading per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events:
- AST (<5.0 x ULN)
- ALT (<5.0 x ULN)
- Total bilirubin (<2.6 x ULN)
- Lipase (<3 x ULN)
- Estimated glomerular filtration rate (eGFR; ≥60 ml/min/1.73 m2)
- Platelets (≥50,000 cells/mm3 or ≥50.00 x 109 cells/L)
- Hemoglobin (≥8.5 g/dL or ≥5.25 mmol/L)
- Neutrophils (≥600 cells/mm3)
Note: Laboratory tests may be repeated during the study screening period (i.e., within 28 days prior to entry), with the latest result used for eligibility determination. ALT and total bilirubin should also be assessed
-
Has no evidence of chronic hepatitis B infection based on hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), and hepatitis B surface antibody (HBsAb) testing at screening; any of the following three combinations of test results are acceptable for inclusion:
- HBsAg negative, HBcAb negative, HBsAb negative
- HBsAg negative, HBcAb negative, HBsAb positive
- HBsAg negative, HBcAb positive, HBsAb positive
-
At screening, has a mean QTc interval (based upon a triplicate reading) less than or equal to 450 msec based on an electrocardiogram (ECG) automated machine readout or calculated using the Fridericia formula.
-
For female participants of childbearing potential, not pregnant based upon negative blood or urine pregnancy test at entry. Childbearing potential is defined as nine years of age or older and:
- Having reached menarche or
- Engaging in sexual activity (self-reported) that could lead to pregnancy
-
For female participants of childbearing potential who are engaging in sexual activity (self-reported) that could lead to pregnancy, at entry, currently using at least one allowable highly effective method of contraception and agrees to use at least one allowable highly effective method of contraception throughout study participation and for at least 30 days after last oral product use and 48 weeks after last injectable study product use.
Highly effective methods of contraception include:
- Surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, tubal ligation, or salpingectomy)
- Contraceptive intrauterine device or intrauterine system
- Subdermal contraceptive implant
- Progestogen injections
- Combined estrogen and progestogen oral contraceptive pills
- Percutaneous contraceptive patch
- Contraceptive vaginal ring
Inclusion Criteria, Step 2: Continuation for Cohort 1 and Cohort 2a to injection phase
All participants enrolled in Cohort 1 or Cohort 2a will be assessed for eligibility to progress from the oral lead-in phase (Step 1) to the injection phase (Step 2), primarily based on the safety assessments from the Step 1 Week 4a study visit. Clinical assessments conducted prior to administering the first injection at the Week 4b visit will also be used to confirm eligibility to receive the injectable study product.
All of the following criteria must be met in order for a participant enrolled in Cohort 1 or Cohort 2a to be included in Step 2
-
Currently enrolled as a participant in Step 1.
-
Has normal, Grade 1, or Grade 2 results from all of the following laboratory test results based upon specimens collected at the Week 4a study visit or from confirmatory repeat testing of Week 4a study visit laboratory tests:
- AST (<5.0 x ULN)
- ALT (<5.0 x ULN)
- Lipase (< 3 x ULN)
- Estimated glomerular filtration rate (eGFR; ≥60 ml/min/1.73 m2))
- Platelets (≥50,000 cells/mm3 or ≥50.00 x 109 cells/L)
- Hemoglobin (≥8.5 g/dL or ≥5.25 mmol/L)
- CK (<10 x ULN)
Note: For a Grade 2 ALT test result from this visit, refer to protocol for required participant management.
- For female participants of childbearing potential not pregnant based upon negative blood or urine pregnancy test at the Week 4b study visit.
- Assessed by the IoR or designee as sufficiently adherent to study products in Step 1 to permit an adequate evaluation of safety and tolerability as part of the oral lead in phase prior to entry into the injection phase.
Inclusion Criteria for Parents/Caregivers
Parents/caregivers of participants will be considered for enrollment to complete quantitative behavioral surveys and/or qualitative in-depth interviews (IDIs), as indicated in the SoE. One parent/caregiver per participant should be enrolled to complete all behavioral assessments, including the IDI, when applicable. Informed consent for parent/caregiver enrollment should be obtained at the entry visit, after the child participant's eligibility has been confirmed, and may be completed at a later date, if necessary. However, parent/caregiver consent must occur prior to any study assessments being conducted. The enrolled caregiver may be the different than the parent or legal guardian who provided written permission for the child to participate. If, at any point the enrolled parent/caregiver for a given participant withdraws from the study or is unable to complete remaining study assessments for any reason, they may be replaced.
Caregivers must meet the following criteria to be eligible to enroll in IMPAACT 2036:
- 18 years of age or older
- Able and willing to provide written informed consent consistent with site IRB/EC policies and procedures
- Caregiver, defined as a biological parent, legal guardian, or other person who provides significant emotional, psychological, and/or physical care to a child enrolled in IMPAACT 2036, based on self-report
Exclusion Criteria, Step 1: Entry for Cohort 1, Cohort 2a, and Cohort 2b
Potential participants must be excluded from the study if any of the conditions specified below are identified during the screening period (i.e., within 28 days prior to study entry). The screening period begins when parental permission and informed assent (if applicable) are obtained and ends immediately prior to enrollment. For criteria involving a potential participant's medical history, it is expected that each exclusionary condition will be assessed at screening and subsequently reviewed and confirmed on the day of study entry, prior to enrollment. In these criteria, "at entry" is used to refer to the day of enrollment in the study
- Within 6 months prior to entry, any HIV-1 RNA value >400 copies/mL OR two consecutive "viral blips," defined as an HIV-1 RNA value ≥50 copies/mL but ≤400 copies/mL.
- As determined by the IoR or designee, and based on available medical records, known or suspected resistance to NNRTIs.
Note: Prior receipt of NNRTIs for prophylaxis or treatment is not exclusionary
-
As determined by the IoR or designee, and based on available medical records, known or suspected resistance to INSTIs.
-
Ongoing congestive heart failure, symptomatic arrhythmia, or any current clinically significant cardiac disease, as determined by the IoR or designee, and based on available medical records.
-
Has any of the following, as determined by the IoR or designee based on participant/parent/guardian report and available medical records:
- Current hepatitis C infection
- Current clinically significant hepatic disease
- Current or anticipated need for chronic anti-coagulation
- History of known or suspected bleeding disorder, including a history of prolonged bleeding
- History of sensitivity to heparin or heparin-induced thrombocytopenia, as determined by the IoR or designee, based on available medical records
- Risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, hypomagnesemia)
- Known or suspected allergy to study product components.
- Known phobia to needles
-
More than one seizure within one year (defined as within 365 days) prior to entry, or unstable or poorly controlled seizure disorder, as determined by the IoR or designee, and based on available medical records.
-
Has the following combination of laboratory test results at screening (i.e., from specimens collected within 28 days prior to entry): ALT greater than or equal to 3 x ULN and total bilirubin greater than or equal to 1.5 x ULN and direct bilirubin greater than 35% of total bilirubin.
-
At entry, known active tuberculosis infection, as determined by the IoR or designee based on participant/parent/guardian report and available medical records.
-
At entry, any ongoing pancreatitis as determined by the IoR or designee based on participant/parent/guardian report and available medical records.
-
At entry, has symptoms suggestive of active coronavirus disease 2019 (COVID-19) or test results or contacts that require quarantine per local clinical practice, public health, and/or infection control guidelines as determined by the IoR or designee based on participant/parent/guardian report and available medical records.
Note: Potential participants with symptoms suggestive of active COVID-19, test results, and/or contacts that require quarantine may resume screening (or be re-screened) after symptoms have resolved and applicable quarantine requirements have been completed.
- Receipt of any prohibited medication within 7 days prior to entry, with the exception of antiviral agents that are part of the participant's ART regimen, as determined by the site investigator based on participant/parent/guardian report and available medical records
Note: Medications and vaccines approved for emergency use (e.g., COVID vaccines) that do not appear in the IMPAACT 2036 Prohibited and Precautionary Medications listing are not exclusionary may be administered as per standard of care.
- Any past or current exposure to CAB LA or RPV LA
- At entry, based on physical examination, has a current inflammatory skin condition that compromises the safety of intramuscular injections, as determined by the IoR or designee.
- At entry, based on physical examination, has a dermatological condition overlying the buttock or upper thigh region, which, in the IoR or designee's opinion, may interfere with the interpretation of injection site reactions.
- Enrolled in another clinical trial of an investigational agent, device, or vaccine.
- Has any documented or suspected clinically significant medical or psychiatric condition or any other condition or social circumstance that, in the opinion of the site investigator, would make participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Exclusion Criteria, Step 2: Continuation for Cohort 1 and Cohort 2a to injection phase
Participants in Cohort 1 or Cohort 2a who meet any of the following criteria will be excluded from Step 2:
- Has permanently discontinued oral study product.
- Occurrence of any grade 3 or higher adverse event assessed as related to study product during Step 1.
- Any other condition or social circumstance situation that, in the opinion of the IoR or designee, would make continued study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Exclusion Criteria for Parents/Caregivers
- Any condition or social circumstance situation that, in the opinion of the IoR or designee, would make study participation unsafe for the caregiver or the child study participant, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Cohort 1
Cohort 1 will receive Once daily oral CAB + oral RPV through the Week 4b visit, followed by intramuscular injection doses of CAB LA + RPV LA every four weeks (Q4W dosing regimen) or every eight weeks (Q8W dosing regimen) |
Tablet Injectable |
|
실험적: Cohort 2A
Cohort 2A: Once daily doses of oral CAB + oral RPV through the Week 4b visit, followed by Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA. |
Tablet Injectable |
|
실험적: Cohort 2B
Cohort 2B: Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA. |
Injectable |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
투여 전 농도(C0)(코호트 1, 정제)
기간: 2주 차에
|
2주 차에
|
|
|
5주차 농도(C5WK)(코호트 1, 주사)
기간: 5주차까지
|
5주차까지
|
|
|
12주차 농도(C12WK)(코호트 1, 주사)
기간: 12주까지
|
12주까지
|
|
|
24주까지 IM 투여 전 최저 농도(Ct)(코호트 1, 주사)
기간: 24주까지
|
24주까지
|
|
|
24주차 및 8주차 축적 비율(코호트 1, 주사)
기간: 8주차와 24주차에
|
8주차와 24주차에
|
|
|
CAB + RPV 경구 도입 기간 동안 약물 관련 안전 사건을 경험한 아동의 비율(코호트 1)
기간: 4a 주까지
|
4a 주까지
|
|
|
CAB + RPV 경구 도입 기간(코호트 1) 동안 3등급 이상의 더 높은 부작용을 경험한 아동의 비율
기간: 4a 주까지
|
4a 주까지
|
|
|
CAB + RPV 경구 도입 기간 동안 SAE를 경험한 아동의 비율(코호트 1)
기간: 4a 주까지
|
4a 주까지
|
|
|
CAB + RPV 경구 도입 기간(코호트 1) 동안 부작용으로 인해 조기 영구 중단 연구 치료를 경험한 아동의 비율
기간: 4a 주까지
|
4a 주까지
|
|
|
CAB + RPV(경구 및 주사 가능)의 24주 동안 약물 관련 안전 실패 사건을 경험한 아동의 비율(코호트 1)
기간: 4b주차부터 28주차까지
|
4b주차부터 28주차까지
|
|
|
CAB + RPV(경구 및 주사 가능)의 24주 동안 3등급 이상의 부작용을 경험한 아동의 비율(코호트 1)
기간: 4b주차부터 28주차까지
|
4b주차부터 28주차까지
|
|
|
CAB + RPV(경구 및 주사 가능)의 24주 동안 SAE를 경험한 아동의 비율(코호트 1)
기간: 4b주차부터 28주차까지
|
4b주차부터 28주차까지
|
|
|
CAB + RPV(경구 및 주사 가능)의 24주 동안 부작용으로 인해 조기 영구 중단 연구 치료를 경험한 아동의 비율(코호트 1)
기간: 4b주차부터 28주차까지
|
4b주차부터 28주차까지
|
|
|
AUC (Cohort 1, tablets)
기간: At week 2
|
Area under the curve from start of dose to 8 hours post dose |
At week 2
|
|
CL/F (Cohort 1, tablets)
기간: At week 2
|
apparent clearance from start of dose to 8 hours post dose |
At week 2
|
|
Cmax (Cohort 1, tablets)
기간: At week 2
|
Peak concentration from start of dose to 8 hours post dose |
At week 2
|
|
Tmax (Cohort 1, tablets)
기간: At week 2
|
Time of maximal concentration from start of dose to 8 hours post dose |
At week 2
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
축적 비율 24주: 8주 및 48주: 8주(코호트 2a), 20주: 4주 및 44주: 4주(코호트 2b)
기간: 8주차, 48주차, 72주차에
|
8주차, 48주차, 72주차에
|
|
|
주까지 IM 투여 전 Ct. 24 및 주. 48(코호트 2a)
기간: 주에. 24 및 주. 48
|
주에. 24 및 주. 48
|
|
|
Wk를 통해 IM 투여 전 Ct. 20주 44(코호트 2b)
기간: 20주차와 44주차에
|
20주차와 44주차에
|
|
|
CAB + RPV(경구 및 주사 가능)(코호트 1)의 48주 및 72주 동안 약물 관련 안전 실패 사건을 경험한 아동의 비율
기간: 48주차와 72주차까지
|
48주차와 72주차까지
|
|
|
CAB + RPV(경구 및 주사 가능)(코호트 1)의 48주 및 72주 동안 3등급 이상의 부작용을 경험한 아동의 비율
기간: 48주차와 72주차까지
|
48주차와 72주차까지
|
|
|
CAB + RPV(경구 및 주사 가능)(코호트 1)의 48주 및 72주 동안 SAE를 경험한 아동의 비율
기간: 48주차와 72주차까지
|
48주차와 72주차까지
|
|
|
CAB + RPV(경구 및 주사 가능)(코호트 1)의 48주 및 72주까지 부작용으로 인해 조기 영구 중단 연구 치료를 경험한 아동의 비율(코호트 1)
기간: 48주차와 72주차까지
|
48주차와 72주차까지
|
|
|
HIV-1 RNA를 가진 어린이의 비율
기간: 24주차, 48주차, 72주차에
|
24주차, 48주차, 72주차에
|
|
|
HIV-1 RNA를 가진 어린이의 비율
기간: 24주차, 48주차, 72주차에
|
24주차, 48주차, 72주차에
|
|
|
CAB + RPV(코호트 1) 치료를 받는 동안 24주, 48주 및 72주차에 바이러스학적 실패가 확인된 소아의 비율
기간: 24주차, 48주차, 72주차에
|
24주차, 48주차, 72주차에
|
|
|
CAB 또는 RPV 부작용, 주사 관련 통증, 및 24주, 48주 및 72주 주사 부위 반응에 대한 설문지에 대한 어린이 및/또는 부모/간병인 응답(코호트 1)
기간: 24주, 48주 및 72주차에
|
24주, 48주 및 72주차에
|
|
|
아동 및/또는 부모/간병인은 24주, 48주 및 72주(코호트 1)에 사용할 의향을 포함하여 CAB 또는 RPV에 대한 태도를 보고했습니다.
기간: 24주차, 48주차, 72주차에
|
24주차, 48주차, 72주차에
|
|
|
24주, 48주 및 72주(코호트 1)에서 CD4 수 및 백분율에 대한 중앙값
기간: 24주차, 48주차, 72주차에
|
24주차, 48주차, 72주차에
|
|
|
24주, 48주 및 72주(코호트 1)에서 기준선 CD4 수 및 백분율로부터 중앙값 변화
기간: 24주차, 48주차, 72주차에
|
24주차, 48주차, 72주차에
|
|
|
아동 및/또는 부모/간병인은 48주 CAB + RPV(경구 및 주사 가능) 또는 44주 CAB LA + RPV LA(주사 가능)에 있는 아동을 위한 사용 의향을 포함하여 CAB(코호트 2) 또는 RPV에 대한 태도를 보고했습니다.
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
CAB + RPV(경구 및 주사제) 48주 또는 CAB LA + RPV LA(주사제) 44주 동안 약물 관련 안전 실패 사건을 경험한 아동의 비율(코호트 2)
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
CAB + RPV(경구 및 주사제) 48주 또는 CAB LA + RPV LA(주사제) 44주 동안 3등급 이상의 부작용을 경험한 아동의 비율(코호트 2)
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
48주 CAB + RPV(경구 및 주사제) 또는 44주 CAB LA + RPV LA(주사제) 동안 SAE를 경험한 아동의 비율(코호트 2)
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
CAB + RPV(경구 및 주사 가능)의 48주 또는 CAB LA + RPV(코호트 2) LA(주사 가능)의 44주 동안 부작용으로 인해 조기 영구 중단 연구 치료를 경험한 아동의 비율
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
HIV-1 RNA를 가진 어린이의 비율
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
HIV-1 RNA를 가진 어린이의 비율
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
CAB + RPV(경구 및 주사) 48주 또는 CAB LA + RPV LA(주사) 44주(코호트 2)의 치료를 받는 동안 바이러스학적 실패가 확인된 소아의 비율(코호트 2)
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
48주 CAB + RPV(경구 및 주사 가능) 또는 44주 CAB LA + RPV LA(주사 가능)에 있는 어린이의 CD4 수 및 백분율에 대한 중앙값 및 사분위수 범위(코호트 2)
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
48주 CAB + RPV(경구 및 주사 가능) 또는 44주 CAB LA + RPV LA(주사 가능)(코호트 2)에 있는 어린이에 대한 기준선 CD4 수 및 백분율로부터 중앙값 및 사분위수 범위 변화
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
LA 투약: Wk에서 IM 투약 전 Ct. 48주 72 및 축적 비율(48주차:8주차 및 72주차:8주차)(코호트 1)
기간: 8주차와 48주차에
|
8주차와 48주차에
|
|
|
CAB + RPV를 투여하는 동안 바이러스학적 실패를 경험한 어린이 중 CAB 또는 RPV에 대한 유전형 및 표현형 저항성을 보인 참가자의 비율(코호트 1)
기간: 72주차까지
|
72주차까지
|
|
|
CAB + RPV(경구 및 주사제) 48주 동안 또는 CAB LA + RPV LA(주사제) 44주 동안 바이러스학적 실패를 경험한 어린이 중 CAB 및 RPV에 대한 유전형 및 표현형 저항성을 보인 참가자의 비율(코호트 2)
기간: 44주차와 48주차에
|
44주차와 48주차에
|
|
|
Child and/or parent/caregiver response to questionnaires (Cohort 2)
기간: at week 44 and 48
|
about CAB or RPV side effects, pain associated with injections and injection site reactions for children who are on 48 weeks of CAB+RPV(oral and injectable) OR 44 weeks of CAB LA+RPV LA (injectable) |
at week 44 and 48
|
기타 결과 측정
기타 결과 측정
결과 측정 |
기간 |
|---|---|
|
최종 IM 투여 후 8~48주 후의 CAB 및 RPV 농도
기간: 8주차와 48주차에
|
8주차와 48주차에
|
|
CAB LA + RPV LA의 영구 중단 후 48주 동안 약물 관련 안전 실패 사건을 경험한 아동의 비율
기간: 48주까지
|
48주까지
|
|
CAB LA + RPV LA의 영구 중단 후 48주 동안 3등급 이상의 부작용을 경험한 소아의 비율
기간: 48주까지
|
48주까지
|
|
CAB LA + RPV LA의 영구 중단 후 48주 동안 SAE를 경험한 아동의 비율
기간: 48주까지
|
48주까지
|
|
PO 투약: Wk. 2 투여 방식에 따른 AUC, CL/F, Cmax, Tmax 및 투여 전 농도(C0)
기간: 2주 차에
|
2주 차에
|
공동 작업자 및 조사자
스폰서
스폰서
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- IMPAACT 2036
- DAIDS Study ID (기타 식별자: 38932)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data that underlie results in the publication, after deidentification.
IPD 공유 기간
Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.
IPD 공유 액세스 기준
With whom?
- Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
- For what types of analyses?
- To achieve aims in the proposal approved by the IMPAACT Network.
- By what mechanism will data be made available?
- Researchers may submit a request for access to data using the IMPAACT "Data Request" form at: https:// www.impaactnetwork.org/ resources/study-proposals.htm. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .